Bioengineering: seventh report of session 2009-10, report, together with formal minutes, oral and written evidence
The Stationery Office, Mar 25, 2010 - Science - 236 pages
This report finds that the UK has an excellent research base but is still failing to maximise its potential by translating research into wealth and health. The road to economic recovery will depend, in part, on exploitation of the UK's research base, which in turn requires efficient translation to generate returns on investments. Some areas of bioengineering, such as stem cells, have clearly benefited from strong Government leadership and support, backed up by generous levels of funding from both the public and private sectors. Others, such as genetically modified (GM) crops, are less well supported and funded. This is curious when GM crops are considered by the Government to be safe and offer potential benefits. GM crops are certainly the poor cousin in the bioengineering family, and we strongly urge the Government to signal its support for GM crops as well as improving the regulatory situation in Europe. Regulation of bioengineering is complex and researchers have found that regulations inhibit research and translation, either because of regulatory complexity (stem cells) or a flawed operation of the regulatory process (GM crops). There are good indications that the UK is learning from past experiences in bioengineering when handling new emerging technologies, such as synthetic biology. The Government and Research Councils have recognised the value of synthetic biology early, and are providing funding. The Committee is also concerned that while research is well funded there is not enough forethought about synthetic biology translation, for example developing DNA synthesis capability, which would provide the UK with an excellent opportunity to get ahead internationally. If this is not addressed, synthetic biology runs the risk of becoming yet another story of the UK failing to capitalise on a strong research base and falling behind internationally.
What people are saying - Write a review
We haven't found any reviews in the usual places.
agricultural applications approval BBSRC benefits bioengineering biotech biotechnology centres Chairman challenges clinical trials collaboration commercial companies Dan Norris Defra disease Dr Harris Dr Iddon embryonic stem cells embryos engineering ensure environment EPSRC ethical Europe European European Medicines Agency example funding gene therapy genetically modified genomics global GM crops Government health research healthcare HFEA impact industry Innovation internationally competitive position investment issues legislation Lord Drayson maintain and grow Martin Evans Memorandum submitted MHRA million OSCHR patients pharmaceutical plant potential Professor Pollock programme public engagement recognised regenerative medicine regulatory framework regulatory system research and translation research base Research Councils risk safety Science and Technology scientific scientists sector stem cell research stem cell therapies Syngenta synthetic biology Technology Strategy Board therapeutic translate and commercialise treatment UK Stem Cell UK's research capacity University